January 14.2025
3 Minutes Read
Discover All-Natural Tyrosinase Inhibitors: Your Key to Bright, Even Skin
1 Views
0 Comments
Related Posts All Posts
02.14.2025
Exploring Fast Track Designation for Rezpegaldesleukin in Atopic Dermatitis Treatment
Update The Significance of Fast Track Designation Nektar Therapeutics has achieved a significant milestone by receiving Fast Track designation from the FDA for its investigational drug, rezpegaldesleukin (Rezpeg), aimed at treating atopic dermatitis (AD). This designation is particularly important as it emphasizes the FDA’s recognition of an urgent need for effective treatments in this area. Jonathan Zalevsky, PhD, chief of research and development at Nektar, explains that such a designation facilitates more access to FDA resources, including the opportunity for frequent consultations and expedited review processes. By focusing on pre-clinical information, this designation underscores the recognition of the unmet healthcare need that remains prevalent despite existing therapies. Understanding Atopic Dermatitis and Current Treatments Atopic dermatitis, affecting around 30 million individuals in the U.S., is a chronic inflammatory skin condition characterized by intense itching and compromised skin barrier. While biologics like dupilumab (Dupixent) and tralokinumab (Adbry) have been introduced, Zalevsky points out that patients often still struggle for optimal disease control. The complexity and variability of AD necessitate advancements beyond the current available therapies. Rezpegaldesleukin hopes to bridge this gap by targeting the interleukin-2 pathway, which presents a different biological approach than traditional treatments like IL-13 inhibitors. What's New About Rezpegaldesleukin? Rezpegaldesleukin is differentiated by its unique mechanism of action. Most existing treatments mainly focus on modulating the IL-13 and IL-4 pathways, but Rezpeg intends to stimulate regulatory T cells through IL-2 modulation. This approach promises unprecedented outcomes, as presented in early studies, which offer hope for those inadequately responded to other treatments. Zalevsky emphasizes that while current therapies can provide relief, the persistence of unmet needs in managing AD illustrates the importance of new solutions like Rezpeg. The Next Steps for Rezpegaldesleukin As Rezpegaldesleukin moves forward with its development, the Fast Track designation allows for more dynamic interaction with the FDA. Nektar anticipates a swift progression through clinical trials, bolstered by the designation that prioritizes the drug in development. Zalevsky affirms the company’s commitment to collaborate closely with the FDA to design a registrational program, indicating a promising future for Rezpeg as it looks to address this significant healthcare challenge. Conclusion: A Hopeful Future for Atopic Dermatitis Patients With rezpegaldesleukin entering the pipeline for accelerated evaluation, patients suffering from atopic dermatitis could soon find hope in a treatment that better targets their specific immunological needs. The emphasis on both regulatory support and innovative drug design illustrates a proactive approach in healthcare, highlighting how continued research and development can lead to improved outcomes for those battling chronic skin conditions.
02.12.2025
Discover How Centella Asiatica Can Revitalize Your Skincare Routine
Update Unlocking the Soothing Secrets of Centella Asiatica If you're in search of a skincare miracle, look no further than Centella Asiatica—an age-old herb making waves in modern beauty regimes. Popular in Korean skincare, Centella not only soothes irritation but also works wonders for collagen production. But what exactly makes this herb a skincare staple? Let’s explore its unique properties, starting from its origins to its benefits for your skin. Centella Asiatica: The Natural Powerhouse Known as Gotu Kola or Pennywort, Centella Asiatica thrives in wetlands across Asia. Traditionally, it has been both a medicinal herb and a culinary ingredient, showcasing its versatile utility. Visually, it features beautiful, green, round leaves, and it also produces charming white or reddish flowers. Its rich heritage in natural remedies makes it a worthy addition to any skincare routine. The Science of Centella: A Closer Look The marvel of Centella lies within its chemical makeup. The extract harnesses a group of compounds called triterpenoids—accounting for 1-8% of its composition. This class of chemicals is celebrated for their ability to promote collagen production and facilitate wound healing, making them potent allies in the fight against skin aging. Other components such as centellose and madecassoside work together to enhance its efficacy. Wound Healing: Centella's Key Benefit Research indicates that triterpenoids act similarly to injected collagen in promoting skin regeneration. While much of the scientific inquiry targets oral or injectable forms of Centella, studies involving topical applications have shown promise, particularly when paired with other ingredients like vitamin C. This combination amplifies the potential benefits, though further studies are needed to understand optimal formulations better. Anti-Inflammatory Properties Chemologically speaking, triterpenoids are also recognized as antioxidants—an essential aspect for those looking to combat inflammation and oxidative stress on the skin. Their anti-inflammatory powers can help soothe redness, boost healing, and even assist with uneven skin tone, making Centella Asiatica a multifaceted addition to your beauty lineup. Transformative Skin Benefits: What to Expect While Centella Asiatica shines in promoting healing and anti-aging, many users find that consistent use helps improve overall skin texture and elasticity. This gentle giant of the skincare world is ideal for sensitive or irritated skin, providing not just relief but a gradual transformation towards a more radiant appearance. Users can expect their skin to feel not just calmer, but also rejuvenated and revitalized. Incorporating Centella into Your Skincare Routine Whether found in creams, serums, or masks, incorporating Centella Asiatica extract into your skincare regimen can enhance your overall skin health. Given its gentle nature, it's perfect for daily use, and you'll likely notice the benefits over time. As this herb gains recognition in the Western world, look for it prominently featured in K-beauty products—and get ready to experience a soothing shift in your skincare routine.
02.11.2025
Closing the Wound Care Gap: Addressing Limb Preservation Disparities
Update The Unseen Crisis: Wound Care Disparities and Limb Loss In the United States, health care disparities continue to plague those coping with limb loss. Recent studies reveal that over 5.6 million Americans live with limb differences, a statistic that highlights an urgent need for equitable access to limb-preservation methods. The road to recovery is often complicated by socioeconomic factors; many individuals lack access to advanced treatments that could prevent amputations. Understanding Historical Context To grasp the current state of wound care, it is essential to look back at the 1990s, a pivotal period during which diabetic limb salvage efforts faced daunting challenges. During my podiatric residency in San Antonio, the available wound care options were limited. Patients suffered from diabetic foot ulcers, and many faced amputation due to a lack of advanced treatments. The progress we have seen today is remarkable, but it shines a light on the disparities that remain. Transformation Through Technology Advancements in medical technology, including human cellular and tissue-based products, have revolutionized limb preservation efforts. These promising techniques have enhanced wound healing and facilitated better patient outcomes. Multi-disciplinary Approaches: A Team Effort The medical community’s awareness of the traumatic impact of amputations has catalyzed a shift towards multidisciplinary care for limb preservation. Today, healthcare providers are encouraged to work collaboratively, combining expertise from various specialties to address complex wound care needs effectively. This team approach not only improves outcomes but also promotes psychological well-being in patients facing limb loss. Future Trends: Bridging the Gap As we head into the future, it is crucial to address existing disparities in wound care. Implementing educational programs and improving access to care for at-risk populations will be key strategies. By promoting awareness of limb-preservation options, we can empower individuals to take charge of their health. Why This Matters Understanding the obstacles that individuals with limb loss face is essential. These insights highlight the importance of advocacy in increasing awareness of wound care disparities. As members of society, we can collectively shape a future where equitable healthcare is available to all, irrespective of background.
Add Row 
Add Element 
Verve Aesthetics Studio focuses on high-tech, non-invasive cosmetic treatments for urban professionals.
Add Element (888) 275-2250
AVAILABLE FROM 8AM - 5PM EST
99 Monon Boulevard, Carmel, IN 46032
Add Element ABOUT US
Verve Aesthetic Studio is the premier destination for cutting-edge insights into non-invasive beauty treatments and aesthetic innovations. Our mission is to empower professionals and consumers with expert knowledge, data-driven analysis, and the latest advancements in MedSpa technology.
Add Element © 2025 Verve Aesthetics Studio All Rights Reserved. 99 Monon Boulevard, Carmel, Indiana 46032 . Contact Us . Terms of Service . Privacy Policy
{"company":"Verve Aesthetics Studio","address":"99 Monon Boulevard","city":"Carmel","state":"Indiana","zip":"46032","email":"kevin@meghan.ai","tos":"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","privacy":"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"}
Write A Comment